Advertisement


Alex Andrea Francoeur, MD, on Endometrial Cancer and Obesity Trends

2024 ASCO Annual Meeting

Advertisement

Alex Andrea Francoeur, MD, of UC Irvine Health, discusses data showing an association between the increasing incidence of endometrial cancer and obesity, which disproportionately affects younger women and women of color. According to Dr. Francoeur, the findings warrant targeted health services and public health interventions to stabilize and ultimately reverse the rising rates (Abstract 5507).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Obesity has been identified to be a risk factor for endometrial cancer, but trends overtime have not been well studied. So the objective of our study was to study the trends of endometrial cancer and obesity from 2001 to 2018 in the United States using a large national database. Additionally, we aim to identify people most at risk based on these findings and identify disparities on a population-based level. For this study, we used the United States Cancer Statistics Database to gather data on endometrial cancer. This database represents over 99% of all cancer cases diagnosed in the United States. We then performed a correction for hysterectomy and pregnancy within this database. For data on obesity, we used the NHANES database, which provides population-based statistics on obesity for the United States. To compare the relationship in trends between endometrial adenocarcinoma and obesity, a Pearson correlation coefficient was calculated for selected groups. We identified 586,000 cases of endometrioid adenocarcinoma from 2001 to 2018. When looking at our obesity data, the majority of the US female population is either overweight or obese. And the majority of Black and Hispanic women are overweight or obese. Endometrioid adenocarcinoma rates are increasing in younger age groups. In the 20 to 29 year old age group, we found that there's been a 137% increase in the rate of endometrial adenocarcinoma since 2001. In the 30 to 39 year old age group, we found that there's been a 71% increase. When looking at trends by race and ethnicity, we found that in Black women, there's been an increase in endometrial cancers of 25% since 2001, and in Hispanic women, there's been an increase of 17%. We then performed a trend analysis of obesity and endometrial cancer in parallel. Rates of obesity are rising at 7.5% in the 20 to 29 year old age group per year. The highest rate of increase in any age group. Rates of endometrial cancer are rising in this age group at 4.5% per year, also the highest of any age group. The correlation coefficient for this age group was 0.78, demonstrating a strong correlation. We see a similar trend in women age 30 to 39 with rates of obesity rising at 4.5% annually, and rates of cancer rising at 3% per year. Again, demonstrating a strong correlation with an R of 0.88. We see similar trends when we look at race and ethnicity, where obesity and endometrioid adenocarcinoma are statistically significantly correlated. In conclusion, the current data, although retrospective, demonstrate a strong temporal association in the rising rates of obesity and endometrioid adenocarcinoma in the United States. This represents a public health emergency, and actions are needed to address the impact of obesity on endometrial cancer. These actions can include increased awareness, medications, targeting weight management, surgical management of obesity, and increased research in this area.

Related Videos

Breast Cancer

Eva M. Ciruelos, MD, PhD, on HER2-Positive and PAM50 Luminal Breast Cancer: Primary Results From the PATRICIA Trial

Eva M. Ciruelos, MD, PhD, of Spain’s Hospital 12 de Octubre and the Instituto de Investigación Sanitaria Hospital 12 de Octubre, discusses phase II data showing that the combination of palbociclib, trastuzumab, and endocrine therapy improved progression-free survival in patients with previously treated PAM50 luminal A or B, HER2-positive advanced breast cancer, as compared with treatment of physicians’ choice (Abstract 1008).

Kidney Cancer

Brian I. Rini, MD, on Renal Cell Carcinoma: Exploratory Biomarker Results

Brian I. Rini, MD, of Vanderbilt Ingram Cancer Center, discusses phase III findings of the KEYNOTE-426 study of pembrolizumab plus axitinib vs sunitinib for patients with advanced renal cell carcinoma. He details the exploratory biomarker results, including RNA sequencing, whole-exome sequencing, and PD-L1 (Abstract 4505).

Breast Cancer

Pierfranco Conte, MD, on Early-Stage Triple-Negative Breast Cancer: Trial Update on Avelumab as Adjuvant Treatment

Pierfranco Conte, MD, of the University of Padua, discusses phase III findings from the A-BRAVE trial, which was designed to evaluate the efficacy of avelumab, an anti–PD-L1 antibody, as adjuvant treatment for patients with early-stage triple-negative breast cancer who are at high risk (LBA500).

Gynecologic Cancers

Don S. Dizon, MD, on Ovarian and Other Extrarenal Clear Cell Carcinomas: Update on Nivolumab and Ipilimumab

Don S. Dizon, MD, of Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, discusses final phase II results of the BrUOG 354 trial showing that, for patients with ovarian and other extrarenal clear cell cancers, nivolumab and ipilimumab warrant further evaluation against standard treatment, given the historically chemotherapy-resistant nature of the disease (LBA5500).

Breast Cancer

Emily L. Podany, MD, on Metastatic Breast Cancer: Racial Differences in Genomic Profiles and Targeted Treatment Use

Emily L. Podany, MD, of Washington University, St. Louis, discusses disparities in the use of PI3K inhibitors for Black patients with estrogen receptor–positive, HER2-negative metastatic breast cancer while other drugs that do not require genomic profiling were similarly used (Abstract 1017). 

Advertisement

Advertisement




Advertisement